DMSO in Plastic Surgery: Limited but Promising Evidence
The evidence for DMSO in plastic surgery is limited to small studies from the 1990s-2010s, but these consistently demonstrate beneficial effects on surgical flap survival, tissue expansion, and fat graft preservation.
Evidence for Effectiveness
The strongest plastic surgery evidence comes from three human clinical studies showing DMSO improves surgical outcomes:
Surgical Flap Survival
A randomized prospective study of 51 patients undergoing mastectomy and inguinal lymphadenectomy demonstrated that topical 60% DMSO applied every 4 hours for 10 days postoperatively significantly reduced flap ischemia (mean area 16.33 units vs. 44.93 units in controls, p=0.01) 1. This represents a nearly 64% reduction in ischemic tissue damage.
In a rabbit model with direct clinical translation, topical DMSO 50% combined with hydrogen peroxide 8% increased random skin flap survival from 71% to 92% (p<0.05), with significantly improved transcutaneous oxygen measurements 2. DMSO alone showed modest non-significant improvement (76% survival), suggesting synergistic effects with oxidative agents.
Tissue Expansion for Breast Reconstruction
A consecutive case series of 40 patients undergoing immediate breast reconstruction showed that topical 60% DMSO applied 30 minutes before each expansion session reduced treatment time from 6 to 4 sessions (p<0.05) and increased inflatable volume per session from 90cc to 120cc 3. Pre-filling tissue pressure was significantly lower in the DMSO group (22.1 vs. 28.4 mmHg), explaining the enhanced expansion capacity.
Fat Graft Preservation
In a rat model, cutaneous DMSO administration preserved fat graft weight and enhanced vascularity compared to controls at 2 months post-transplantation 4. The cutaneous route proved superior to intraperitoneal administration, with significantly lower inflammatory markers (myeloperoxidation).
Mechanism of Action in Plastic Surgery
DMSO's effectiveness stems from multiple properties relevant to reconstructive surgery:
- Free radical scavenging: Reduces oxidative tissue damage in ischemic flaps [@1,2,3,4@]
- Enhanced tissue penetration: Facilitates drug delivery and potentially improves tissue compliance 3
- Vasodilation: Improves tissue perfusion in compromised flaps 2
- Anti-inflammatory effects: Reduces postoperative inflammation 4
- Collagen softening: Permits greater tissue expansion 5
Clinical Application Protocol
Based on the available evidence, the following protocols have demonstrated efficacy:
For surgical flaps (mastectomy, lymphadenectomy):
- Apply topical 60% DMSO every 4 hours for 10 days postoperatively
- Cover entire flap area with soaked gauze 1
For tissue expansion:
- Apply topical 60% DMSO via soaking-wet surgical sponges 30 minutes before each filling session
- Leave in place for full 30-minute duration 3
For random skin flaps (experimental):
- Combine DMSO 50% with hydrogen peroxide 8%
- Apply 20ml topically three times daily for 7 days starting immediately postoperatively 2
Important Caveats and Limitations
Study Quality Issues
All plastic surgery studies are small, single-center investigations from 1996-2016 with no recent replication. The highest quality study enrolled only 51 patients 1. No large multicenter trials exist.
FDA Approval Status
DMSO is FDA-approved only for interstitial cystitis [@13,14@]. All plastic surgery applications represent off-label use. The FDA label specifically notes that lens changes occurred in animals receiving chronic high doses, requiring periodic eye examinations 6.
Context from Other Specialties
The guideline evidence provided relates primarily to:
- Chemotherapy extravasation management where DMSO 99% topically is recommended for anthracyclines, mitomycin C, and platinum salts [@1,2,3,4@]
- Testicular tissue cryopreservation where DMSO 1.4-1.5M is the preferred cryoprotectant [@6,7,8,9,10@]
These applications demonstrate DMSO's tissue-protective properties but don't directly address plastic surgery indications.
Safety Considerations
- Garlic-like breath odor is common and may affect patient acceptance
- Local erythema can occur, potentially confounding assessment of tissue viability 7
- Teratogenic in animals at high doses; avoid in pregnancy 6
- Potentiates other medications; review drug interactions 6
- Requires periodic monitoring of liver/renal function and complete blood counts with chronic use 6
Clinical Bottom Line
DMSO shows consistent benefit in small human studies for improving surgical flap survival and accelerating tissue expansion, but the evidence base is dated and limited. The 64% reduction in flap ischemia 1 and 33% reduction in expansion time 3 represent clinically meaningful improvements. However, the lack of recent large-scale validation studies and FDA approval for these indications means adoption requires informed patient consent regarding off-label use.
The mechanism-based rationale is sound, the safety profile is acceptable for short-term topical use, and the cost is minimal. For high-risk flaps or challenging tissue expansion cases, topical 60% DMSO represents a reasonable adjunctive therapy based on available evidence, with appropriate patient counseling about off-label status.